- Home
- CTO vs MLYS Comparison
CTO vs MLYS Comparison
Compare CTO & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | MLYS |
|---|---|---|
| Founded | 1902 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.9M | 3.1B |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | CTO | MLYS |
|---|---|---|
| Price | $18.17 | $37.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $22.00 | ★ $47.33 |
| AVG Volume (30 Days) | 302.9K | ★ 1.6M |
| Earning Date | 10-28-2025 | 11-10-2025 |
| Dividend Yield | ★ 8.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $146,948,000.00 | N/A |
| Revenue This Year | $20.87 | N/A |
| Revenue Next Year | $4.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.84 | N/A |
| 52 Week Low | $15.07 | $8.24 |
| 52 Week High | $20.88 | $47.65 |
Technical Indicators
Market Signals| Indicator | CTO | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 56.97 | 43.48 |
| Support Level | $17.65 | $36.01 |
| Resistance Level | $18.64 | $39.15 |
| Average True Range (ATR) | 0.29 | 1.81 |
| MACD | -0.02 | -0.16 |
| Stochastic Oscillator | 47.71 | 31.53 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.